Update of transmission modelling and projections of gambiense human African trypanosomiasis in the Mandoul focus, Chad.
Diagnostics
Elimination of transmission
Gambiense human African trypanosomiasis (gHAT)
Glossina
Modelling
Tsetse
Validation
Vector control
Journal
Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645
Informations de publication
Date de publication:
24 Jan 2022
24 Jan 2022
Historique:
received:
14
10
2021
accepted:
03
01
2022
entrez:
25
1
2022
pubmed:
26
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
In recent years, a programme of vector control, screening and treatment of gambiense human African trypanosomiasis (gHAT) infections led to a rapid decline in cases in the Mandoul focus of Chad. To represent the biology of transmission between humans and tsetse, we previously developed a mechanistic transmission model, fitted to data between 2000 and 2013 which suggested that transmission was interrupted by 2015. The present study outlines refinements to the model to: (1) Assess whether elimination of transmission has already been achieved despite low-level case reporting; (2) quantify the role of intensified interventions in transmission reduction; and (3) predict the trajectory of gHAT in Mandoul for the next decade under different strategies. Our previous gHAT transmission model for Mandoul was updated using human case data (2000-2019) and a series of model refinements. These include how diagnostic specificity is incorporated into the model and improvements to the fitting method (increased variance in observed case reporting and how underreporting and improvements to passive screening are captured). A side-by-side comparison of fitting to case data was performed between the models. We estimated that passive detection rates have increased due to improvements in diagnostic availability in fixed health facilities since 2015, by 2.1-fold for stage 1 detection, and 1.5-fold for stage 2. We find that whilst the diagnostic algorithm for active screening is estimated to be highly specific (95% credible interval (CI) 99.9-100%, Specificity = 99.9%), the high screening and low infection levels mean that some recently reported cases with no parasitological confirmation might be false positives. We also find that the focus-wide tsetse reduction estimated through model fitting (95% CI 96.1-99.6%, Reduction = 99.1%) is comparable to the reduction previously measured by the decline in tsetse catches from monitoring traps. In line with previous results, the model suggests that transmission was interrupted in 2015 due to intensified interventions. We recommend that additional confirmatory testing is performed in Mandoul to ensure the endgame can be carefully monitored. More specific measurement of cases, would better inform when it is safe to stop active screening and vector control, provided there is a strong passive surveillance system in place.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years, a programme of vector control, screening and treatment of gambiense human African trypanosomiasis (gHAT) infections led to a rapid decline in cases in the Mandoul focus of Chad. To represent the biology of transmission between humans and tsetse, we previously developed a mechanistic transmission model, fitted to data between 2000 and 2013 which suggested that transmission was interrupted by 2015. The present study outlines refinements to the model to: (1) Assess whether elimination of transmission has already been achieved despite low-level case reporting; (2) quantify the role of intensified interventions in transmission reduction; and (3) predict the trajectory of gHAT in Mandoul for the next decade under different strategies.
METHOD
METHODS
Our previous gHAT transmission model for Mandoul was updated using human case data (2000-2019) and a series of model refinements. These include how diagnostic specificity is incorporated into the model and improvements to the fitting method (increased variance in observed case reporting and how underreporting and improvements to passive screening are captured). A side-by-side comparison of fitting to case data was performed between the models.
RESULTS
RESULTS
We estimated that passive detection rates have increased due to improvements in diagnostic availability in fixed health facilities since 2015, by 2.1-fold for stage 1 detection, and 1.5-fold for stage 2. We find that whilst the diagnostic algorithm for active screening is estimated to be highly specific (95% credible interval (CI) 99.9-100%, Specificity = 99.9%), the high screening and low infection levels mean that some recently reported cases with no parasitological confirmation might be false positives. We also find that the focus-wide tsetse reduction estimated through model fitting (95% CI 96.1-99.6%, Reduction = 99.1%) is comparable to the reduction previously measured by the decline in tsetse catches from monitoring traps. In line with previous results, the model suggests that transmission was interrupted in 2015 due to intensified interventions.
CONCLUSIONS
CONCLUSIONS
We recommend that additional confirmatory testing is performed in Mandoul to ensure the endgame can be carefully monitored. More specific measurement of cases, would better inform when it is safe to stop active screening and vector control, provided there is a strong passive surveillance system in place.
Identifiants
pubmed: 35074016
doi: 10.1186/s40249-022-00934-8
pii: 10.1186/s40249-022-00934-8
pmc: PMC8785021
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Subventions
Organisme : Bill and Melinda Gates Foundation
ID : OPP1177824
Organisme : Bill and Melinda Gates Foundation
ID : INV-005121
Organisme : Bill and Melinda Gates Foundation
ID : OPP1184344
Organisme : Bill and Melinda Gates Foundation
ID : INV-008412
Organisme : Bill and Melinda Gates Foundation
ID : INV-001785
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S01375X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S00243X/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/P005888/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
PLoS Negl Trop Dis. 2020 Oct 16;14(10):e0008270
pubmed: 33064783
Trop Med Infect Dis. 2020 Jan 01;5(1):
pubmed: 31906341
PLoS One. 2017 Jul 3;12(7):e0180555
pubmed: 28672036
Trends Parasitol. 2018 Mar;34(3):197-207
pubmed: 29396200
World Health Organ Tech Rep Ser. 2013;(984):1-237
pubmed: 24552089
PLoS One. 2017 Oct 12;12(10):e0186429
pubmed: 29023573
PLoS Negl Trop Dis. 2017 Jul 27;11(7):e0005792
pubmed: 28750007
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003822
pubmed: 26267814
PLoS Comput Biol. 2013;9(1):e1002855
pubmed: 23341760
J Infect Dis. 2020 Jun 11;221(Suppl 5):S539-S545
pubmed: 31876949
PLoS Negl Trop Dis. 2020 Nov 12;14(11):e0008738
pubmed: 33180776
Parasit Vectors. 2015 Oct 22;8:532
pubmed: 26490248
BMC Res Notes. 2015 Jul 04;8:292
pubmed: 26140922
PLoS Negl Trop Dis. 2016 Apr 08;10(4):e0004608
pubmed: 27058033
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e917
pubmed: 21200417
Int Health. 2021 Sep 3;13(5):480-481
pubmed: 33594422
Clin Infect Dis. 2021 Jun 14;72(Suppl 3):S146-S151
pubmed: 33905480
PLoS Negl Trop Dis. 2015 Aug 12;9(8):e0003727
pubmed: 26267667
PLoS Negl Trop Dis. 2021 Jun 11;15(6):e0009407
pubmed: 34115754
Trans R Soc Trop Med Hyg. 2021 Mar 6;115(3):245-252
pubmed: 33611586
PLoS Negl Trop Dis. 2015 Mar 26;9(3):e0003624
pubmed: 25811956
Prev Vet Med. 2013 Jul 1;110(3-4):290-303
pubmed: 23453892
J R Soc Interface. 2020 Dec;17(173):20200540
pubmed: 33292098
PLoS Negl Trop Dis. 2017 Nov 13;11(11):e0006060
pubmed: 29131822
PLoS Negl Trop Dis. 2021 Jun 28;15(6):e0009404
pubmed: 34181651
PLoS Negl Trop Dis. 2020 Apr 9;14(4):e0008033
pubmed: 32271755
Emerg Infect Dis. 2021 Aug;27(8):2144-2153
pubmed: 34287133
PLoS Comput Biol. 2021 Jan 29;17(1):e1008532
pubmed: 33513134
Epidemics. 2017 Mar;18:101-112
pubmed: 28279451
PLoS Negl Trop Dis. 2020 May 21;14(5):e0008261
pubmed: 32437391
PLoS Negl Trop Dis. 2020 Jan 21;14(1):e0007976
pubmed: 31961872
PLoS Negl Trop Dis. 2012;6(6):e1691
pubmed: 22720107
PLoS Negl Trop Dis. 2011 Jul;5(7):e1233
pubmed: 21750745